132 related articles for article (PubMed ID: 10762136)
1. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates.
Jenner P
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S90-9; discussion S99-104. PubMed ID: 10762136
[TBL] [Abstract][Full Text] [Related]
2. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
3. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
5. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
[TBL] [Abstract][Full Text] [Related]
7. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
8. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
Blanchet PJ; Gomez-Mancilla B; Bédard PJ
J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Fox SH; Henry B; Hill M; Crossman A; Brotchie J
Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
[TBL] [Abstract][Full Text] [Related]
10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
11. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
12. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
Crossman AR
Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
[TBL] [Abstract][Full Text] [Related]
13. Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Langston JW; Quik M; Petzinger G; Jakowec M; Di Monte DA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S79-89. PubMed ID: 10762135
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
Bézard E; Ferry S; Mach U; Stark H; Leriche L; Boraud T; Gross C; Sokoloff P
Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of levodopa-induced dyskinesia.
Nutt JG
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?
Bédard PJ; Mancilla BG; Blanchette P; Gagnon C; Di Paolo T
Can J Neurol Sci; 1992 Feb; 19(1 Suppl):134-7. PubMed ID: 1571858
[TBL] [Abstract][Full Text] [Related]
17. Preventing levodopa-induced dyskinesias.
Olanow CW; Obeso JA
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
[TBL] [Abstract][Full Text] [Related]
18. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ
Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
Rascol O; Brefel-Courbon C; Blin O
Therapie; 1998; 53(1):43-8. PubMed ID: 9773099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
